Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug clearance

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,062 result(s) found for: Drug clearance. Displaying page 10 of 104.
    EudraCT Number: 2005-001596-34 Sponsor Protocol Number: CLL2M Start Date*: 2006-04-10
    Sponsor Name:Universität zu Köln
    Full Title: Multicentre phase II trial of Bendamustine in combination with rituximab for patients with previously untreated or relapsed chronic lymphocytic leukemia
    Medical condition: previously untreated or relapsed chronic lymphocytic leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005738-12 Sponsor Protocol Number: LIPSTIC.V.01 Start Date*: 2013-03-27
    Sponsor Name:Alder Hey Children's NHS Foundation Trust
    Full Title: Liverpool Pharmacokinetic/pharmacodynamics study of teicoplanin in children (LIPSTIC).
    Medical condition: Gram-positive bacterial infection: late-onset neonatal sepsis, central line-associated blood stream infection, ventilator-associated pneumonia.
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004280-31 Sponsor Protocol Number: 04/280507 Start Date*: 2006-02-02
    Sponsor Name:University of Dundee
    Full Title: Hyperthermic Intraperitoneal Chemotherapy - Gastric Cancer
    Medical condition: Gastric Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-018373-38 Sponsor Protocol Number: RG_09-071 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Birmingham
    Full Title: A Phase I trial of figitumumab, an IGF-1R antibody, in children aged 1-12 years old with relapsed/refractory Solid Tumours
    Medical condition: Paediatric patients aged 1-12 years with relapsed / refractory solid tumours.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004137-27 Sponsor Protocol Number: ScanCLAD_1.0(formerVersion_0.1) Start Date*: 2016-05-19
    Sponsor Name:Transplantationscentrum, Sahlgrenska Universitetssjukhuset
    Full Title: A Scandinavian controlled, randomized, open-label, and multi-centre study evaluating if once-daily tacrolimus or twice-daily cyclosporin, reduces the 3-year incidence of chronic lung allograft dysf...
    Medical condition: Recipients of primary bilateral lung transplant allograft
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002728-35 Sponsor Protocol Number: HUN-AVI-01 Start Date*: 2020-09-17
    Sponsor Name:Hungarian Ministry of Innovation and Technology - Representative: Hecrin Consortium
    Full Title: An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients with Mild Pneumonia − An open-label randomized controlled study −
    Medical condition: Patients with new type of coronavirus (SARS-CoV-2) infection proven by RT-PCR test with mild pneumonia.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001178-13 Sponsor Protocol Number: NMSG#24/15 Start Date*: 2017-02-02
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Phase 2 study of carfilzomib + elotuzumab + dexamethasone for relapsed or progressed multiple myeloma after 1-3 prior treatment lines
    Medical condition: Multiple myeloma patients
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10067095 Multiple myeloma progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001532-11 Sponsor Protocol Number: 01apr2014 Start Date*: 2014-09-11
    Sponsor Name:Ospedale San Raffaele
    Full Title: MONO-INSTITUTIONAL PHASE II TRIAL ADDRESSING TOLERABILITY AND ACTIVITY OF R-CHOP CHEMOIMMUNOTHERAPY PRECEDED BY BLOOD-BRAIN BARRIER PERMEABILIZATION BY NGR-TUMOR NECROSIS FACTOR IN PATIENTS WITH RE...
    Medical condition: Primary non-Hodgkin lymphoma in the central nervous system relapse / refractory
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004460-22 Sponsor Protocol Number: 5012005 Start Date*: 2006-05-12
    Sponsor Name:Hopital Erasme
    Full Title: Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to corticosteroids with ACE-inhibitors in the treatment of de novo n...
    Medical condition: focal and segmental glomerulosclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004469-40 Sponsor Protocol Number: 5022005 Start Date*: 2006-05-12
    Sponsor Name:Hopital Erasme
    Full Title: Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to ACE-inhibitors alone in the treatment of de novo nephrotic syndro...
    Medical condition: Membranous Nephropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002095-93 Sponsor Protocol Number: GS-US-236-0140 Start Date*: 2014-09-24
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF or other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir p...
    Medical condition: Human Immunodeficiency Virus, Type 1 (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000754-38 Sponsor Protocol Number: TMC114FD2HTX3001 Start Date*: 2015-08-19
    Sponsor Name:Janssen Sciences Ireland UC
    Full Title: A Phase 3, randomized, active-controlled, double-blind study to evaluate efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once daily fixed dose combinatio...
    Medical condition: Human Immunodeficiency Virus Type 1
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) GB (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000451-41 Sponsor Protocol Number: HO150 Start Date*: 2019-03-01
    Sponsor Name:HOVON Foundation
    Full Title: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therap...
    Medical condition: AML or MDS-EB2 with a mutation in either IDH1 or IDH2
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001941 AML LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068361 MDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) FI (Trial now transitioned) LT (Trial now transitioned) SE (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) NO (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002443-28 Sponsor Protocol Number: ACE-CL-311/D8221C00001 Start Date*: 2019-05-08
    Sponsor Name:Acerta Pharma B.V.
    Full Title: A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investiga...
    Medical condition: Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted) HU (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003414-12 Sponsor Protocol Number: HDP-101-01 Start Date*: 2021-09-09
    Sponsor Name:Heidelberg Pharma AG
    Full Title: A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma Cell Disorders Including Multiple Myeloma
    Medical condition: Relapsed or refractory Multiple Myeloma (r/r MM)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004914-79 Sponsor Protocol Number: CA017-003 Start Date*: 2016-10-22
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
    Medical condition: Advanced Malignant Tumors
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PL (Completed) NO (Completed) FI (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-008262-12 Sponsor Protocol Number: GFM-Len-Epo-08 Start Date*: 2009-10-05
    Sponsor Name:Groupe Francophone des Myélodysplasies
    Full Title: A phase II study evaluating the efficacy and safety of Lenalidomide (Revlimid®) with or without Epoetin beta (NeoRecormon®) in transfusion-dependent ESA-resistant patients with IPSS low- and interm...
    Medical condition: patients with IPSS low- and intermediate-1 risk myelodysplastic syndromes without chromosome 5 abnormality
    Disease: Version SOC Term Classification Code Term Level
    12.0 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001268-44 Sponsor Protocol Number: MDCO-CLV-12-01 Start Date*: 2013-09-10
    Sponsor Name:Chiesi USA, Inc.
    Full Title: Open label study to assess the efficacy, safety and dosing of clevidipine in pediatric patients undergoing surgery.
    Medical condition: Blood pressure management in pediatric patients in the perioperative setting. Treatment of hypertensive patients and normotensive patients who require lowering of blood pressure for the procedure.
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-004623-36 Sponsor Protocol Number: MEGALiT1901 Start Date*: 2019-11-29
    Sponsor Name:Uppsala University Hospital
    Full Title: A MolEcularly Guided Anti-Cancer Drug Off-Label Trial – a multicenter, basket and umbrella explorative trial on the efficacy and safety of molecular profile selected commercially available targete...
    Medical condition: In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004108-16 Sponsor Protocol Number: HOFATA_v3.0 Start Date*: 2022-04-21
    Sponsor Name:Medical University Vienna
    Full Title: Host factors predicting target site concentration of antibiotics in critically ill patients: An explorative pharmacokinetic biomarker study
    Medical condition: All patients given standard of care intravenous therapy of the studied antibiotics will be screened against the inclusion criteria. Two groups are included: Group A (septic patients with organ dysf...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 15 23:37:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA